Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local mesenchymal stem cell injection after endoscopic dilation in Crohn's intestinal strictures
2024-511034-12-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Sep 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic bone marrow-derived mesenchymal stromal cells in Crohn's disease and Bowel stenosis (2 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoints: Safety: occurrence of adverse events up to week 48 and Primary efficacy composite response at week 48. Planned start Sep 2024; status: authorised.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
Crohn's diseaseBowel stenosis
Beyond the preview
Go deeper on 2024-511034-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511034-12-00.